Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Assets Average (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Assets Average for 5 consecutive years, with $282.1 million as the latest value for Q1 2026.

  • For Q1 2026, Assets Average fell 16.1% year-over-year to $282.1 million; the TTM value through Mar 2026 reached $282.1 million, down 16.1%, while the annual FY2025 figure was $318.7 million, 19.53% down from the prior year.
  • Assets Average hit $282.1 million in Q1 2026 for Phathom Pharmaceuticals, up from $249.7 million in the prior quarter.
  • Across five years, Assets Average topped out at $385.2 million in Q1 2024 and bottomed at $154.4 million in Q1 2023.
  • Average Assets Average over 5 years is $272.0 million, with a median of $261.6 million recorded in 2023.
  • Year-over-year, Assets Average surged 149.45% in 2024 and then tumbled 34.74% in 2025.
  • Phathom Pharmaceuticals' Assets Average stood at $183.4 million in 2022, then skyrocketed by 77.46% to $325.4 million in 2023, then rose by 17.6% to $382.7 million in 2024, then plummeted by 34.74% to $249.7 million in 2025, then grew by 12.98% to $282.1 million in 2026.
  • According to Business Quant data, Assets Average over the past three periods came in at $282.1 million, $249.7 million, and $245.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.